TEIPL: Technology, Entrepreneurship and Innovation Policy Lab
"We believe this Lab will have a significant impact on Entrepreneurship, Innovation and health policies. Through this work, we will promote a high quality research capacity across Europe. Through the teaming of institutions both in Portugal and the USA and twinning of research staff. We will actively exchange best practices/experience and results by widening excellence and participation to other members that will be encouraged to join." Pedro Oliveira and Lee Branstetter
Research Teams: Carnegie Mellon University (CMU); Universidade Católica Portuguesa (UCP); Instituto de Medicina Molecular (IMM-FMUL); Instituto Superior Técnico (IST-UL)
Organizations: innosabi GmbH (INNOSABI); Microsoft (MSFT); Novartis Farma - Produtos Farmacêuticos S.A. (NOVARTIS)
Main Research Unit: Unidade de Investigação em Ciências Económicas e Empresariais (UNICEE)
Funding Reference: FCT CMUP-ERI/TPE/0028/2013
Duration: 48 months
Keywords: User Innovation; Technology-based Entrepreneurship; Innovation Policy; Innovation in the Health-care Sector
The Technology, Entrepreneurship and Innovation Laboratory (hereinafter referred to as The Lab) is a new multidisciplinary organization that brings together leading academic and corporate partners. We aim to create a world class research and policy center that investigates technological innovation by both users and producers in order to achieve socio-economic wealth. Its mission is to conduct research and policy analyses on the development and diffusion of entrepreneurship and innovation to unlock Portugal’s global competitiveness.
The Lab will build upon the existing expertise of the Carnegie Mellon Portugal Program in entrepreneurship, technological change and innovation, and extend to the areas of healthcare and technology. The educational arm of The Lab is the existing dual Doctoral Program in Technological Change and Entrepreneurship. The academic partners include Católica-Lisbon, IST-UL, IMM-FMUL and CMU, while the initial cohort of corporate partners are Novartis, Microsoft, and innosabi. Microsoft brings in technological expertise to explore ways technology can facilitate and enhance interactions among users and other stakeholders in different settings and access to communication channels; also, they contribution may be important in considering the ways of data acquisition and aggregation from heterogeneous data sources (individual users/ online communities / software applications, etc.), in unstructured environment, and in a safe manner with respect to data protection and other privacy related issues. Novartis brings in an important set of expertise in healthcare from the perspective of a pharmaceutical company. Innosabi is the platform technology developer with strong expertise in co-creation and innovation platforms. Researchers from reputable institutions (such as MIT, NYU, Mass General Hospital, and Bocconi) will participate on an individual basis.
Patient Innovation: Innovative Medical Solutions [SIC]
The Phase II of the Carnegie Mellon Portugal Program emphasizes advanced education and research that can lead to significant entrepreneurial impact. The activities of the program are for the most part configured in Entrepreneurial Research Initiatives (ERIs).
Research Opportunities more